Quality of life (QL) in metastatic castration resistant prostate cancer (mCRPC) treated in first line with new antiandrogens (NA)I. Rivero Belenchón, C. Muñoz Calahorro, I. Osmán García, C.B. Congregado Ruíz, C. Baena Villamarín, G. Lendínez Cano, J.M. Conde Sánchez, R.A. Medina López, J.P. Pedraza SanchezEuropean Urology Supplements（2019）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
